Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.

Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S.

JAMA Oncol. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836.

2.

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.

Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E.

J Immunother Cancer. 2019 Apr 15;7(1):105. doi: 10.1186/s40425-019-0586-0. Review.

3.

Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys.

Xiong Y, Walker K, Min X, Hale C, Tran T, Komorowski R, Yang J, Davda J, Nuanmanee N, Kemp D, Wang X, Liu H, Miller S, Lee KJ, Wang Z, Véniant MM.

Sci Transl Med. 2017 Oct 18;9(412). pii: eaan8732. doi: 10.1126/scitranslmed.aan8732. Erratum in: Sci Transl Med. 2018 Aug 29;10(456):.

PMID:
29046435
4.

C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.

Du X, Hinklin RJ, Xiong Y, Dransfield P, Park J, Kohn TJ, Pattaropong V, Lai S, Fu Z, Jiao X, Chow D, Jin L, Davda J, Veniant MM, Anderson DA, Baer BR, Bencsik JR, Boyd SA, Chicarelli MJ, Mohr PJ, Wang B, Condroski KR, DeWolf WE, Conn M, Tran T, Yang J, Aicher TD, Medina JC, Coward P, Houze JB.

ACS Med Chem Lett. 2014 Nov 22;5(12):1284-9. doi: 10.1021/ml500341w. eCollection 2014 Dec 11.

5.

A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.

Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs J.

MAbs. 2014 Jul-Aug;6(4):1094-102. doi: 10.4161/mabs.29095. Epub 2014 May 16.

6.

Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours.

Baheti G, McGuire TR, Davda JP, Manouilov KK, Wall D, Gwilt PR, Gordon BB.

Xenobiotica. 2013 Mar;43(3):276-82. doi: 10.3109/00498254.2012.713530. Epub 2012 Aug 29.

PMID:
22931186
7.

Synthetic clonal reproduction through seeds.

Marimuthu MP, Jolivet S, Ravi M, Pereira L, Davda JN, Cromer L, Wang L, Nogué F, Chan SW, Siddiqi I, Mercier R.

Science. 2011 Feb 18;331(6019):876. doi: 10.1126/science.1199682.

8.

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.

Davda JP, Hansen RJ.

MAbs. 2010 Sep-Oct;2(5):576-88. doi: 10.4161/mabs.2.5.12833. Epub 2010 Sep 1.

9.

A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.

Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH.

Int Immunopharmacol. 2008 Mar;8(3):401-13. doi: 10.1016/j.intimp.2007.10.023. Epub 2007 Nov 26.

PMID:
18279794
10.

Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.

Wang D, Sima M, Mosley RL, Davda JP, Tietze N, Miller SC, Gwilt PR, Kopecková P, Kopecek J.

Mol Pharm. 2006 Nov-Dec;3(6):717-25.

11.
12.

The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers.

Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH.

Pharm Res. 2004 Apr;21(4):641-8.

PMID:
15139521
13.

Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis.

Qaddoumi MG, Gukasyan HJ, Davda J, Labhasetwar V, Kim KJ, Lee VH.

Mol Vis. 2003 Oct 15;9:559-68.

14.

Characterization of nanoparticle uptake by endothelial cells.

Davda J, Labhasetwar V.

Int J Pharm. 2002 Feb 21;233(1-2):51-9.

PMID:
11897410
15.

An update on angiogenesis therapy.

Davda J, Labhasetwar V.

Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.

PMID:
11693956

Supplemental Content

Support Center